Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients With Ornithine Transcarbamylase Deficiency

NCT04442347 is registered in ClinicalTrials.gov with Arcturus Therapeutics, Inc. as lead sponsor.

NCT NCT04442347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04442347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients With Ornithine Transcarbamylase Deficiency
Lead sponsor
Arcturus Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 3, 2020
Completion date
April 30, 2024
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ornithine transcarbamylase deficiency